AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00005669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control capsules for metformin
Trial: NCT00424268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02253810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution
Trial: NCT04107480
Drug: Dopamine Agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care.
Trial: NCT02212821
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02212821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological saline
Trial: NCT01925300
Drug: Concor 5mg 2T and Crestor 20 mg 1Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00987701
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
Trial: NCT00653354
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
Trial: NCT00653354
Drug: valdecoxib/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
Trial: NCT00653354
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
Trial: NCT03130452
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500mg tablet
Trial: NCT02241187
Drug: PEGPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03919461
Drug: Propranolol and etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A perioperative combined drug regimen
Trial: NCT02048215
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
Trial: NCT03603795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo concomitant with induction chemotherapy patients with AML
Trial: NCT02048215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
Trial: NCT01868633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01437228
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO İNTERVENTİON
Trial: NCT00617955
Drug: Aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: compare outcomes of Aprotinin versus Amicar
Trial: NCT03445390
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 g intravenous given at the beginning and end of surgery.
Trial: NCT03445390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match acetaminophen given at the beginning and end of surgery.
Trial: NCT00688766
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
Trial: NCT02211469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04197661
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Trial: NCT04328961
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
Trial: NCT03806582
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intervention with norepinephrine to reach a MAP of 85 mmHg
Trial: NCT01723228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01387607
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily
Trial: NCT03553316
Drug: PK101-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -(Single) PK101-002
Trial: NCT00689481
Drug: U0267 Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
Trial: NCT03212963
Drug: Halobetasol Topical Lotion
RxNorm normalized name: halobetasol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
Trial: NCT02326142
Drug: OBE001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
Trial: NCT02326142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dispersible tablets for a single oral dose a day for up to 7 days.
Trial: NCT00649181
Drug: Zaroloxyn® Tablets 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x5mg, single dose fasting
Trial: NCT03265093
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection
Trial: NCT03865290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral matched placebo
Trial: NCT02871843
Drug: TMZ Maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMZ maintenance at 150-200 mg/m2
Trial: NCT03063359
Drug: Intranasal fentanyl + Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
Trial: NCT00214955
Drug: ORAVESCENT Fentanyl Citrate
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04651959
Drug: AVICOD 200 MG Film Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
Trial: NCT04651959
Drug: AVIGAN 200 MG Film Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
Trial: NCT02659865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02659865
Drug: LY3039478 original formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02659865
Drug: LY3039478 new formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01285765
Drug: RCHOP21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
Trial: NCT04433013
Drug: Lianhua Qingwen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
Trial: NCT04433013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
Trial: NCT00646204
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tabs bid
Trial: NCT01188057
Drug: NIRAVAM TM 2 mg orally disintegrating tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
Trial: NCT02582840
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet. Oral dose
Trial: NCT02208791
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00486122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03789552
Drug: T89 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T89 capsules (75mg)
Trial: NCT03789552
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (0mg)
Trial: NCT02356809
Drug: Neovasculgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
Trial: NCT02223481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00235950
Drug: Rosuvastatin or atorvastatin or simvastatin and clopidogrel
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00963768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
Trial: NCT01872871
Drug: Topical anaesthetic drop with placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03949075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
Trial: NCT01806649
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006219
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006219
Drug: prasterone
RxNorm normalized name: Prasterone
DrugBank: Prasterone sulfate (DB05804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00417183
Drug: Arvekap 0.1 mg (Triptorelin, Ipsen, France)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01204866
Drug: Valortim and Selected Components
RxNorm normalized name: 1,3-beta-glucan synthase component FKS1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively
Trial: NCT01631474
Drug: CB-03-01
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream, applied once a day
Trial: NCT01631474
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream, applied once or twice a day
Trial: NCT01631474
Drug: CB-03-01
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream, applied twice a day
Trial: NCT00958776
Drug: Placebo+SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Trial: NCT00062426
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00062426
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00062426
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00263523
Drug: [11C] (-)-RWAY
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02514252
Drug: Fentanyl Sublingual Spray (FSS)
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks.
Trial: NCT02053727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00632697
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00261482
Drug: norelgestromin + ethinyl estradiol
RxNorm normalized name: ethinyl estradiol / norelgestromin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03314805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
Trial: NCT04429022
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op
Trial: NCT04429022
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg PO q 12h x 7d post op
Trial: NCT04429022
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg IV once at end of hysterectomy procedure
Trial: NCT00333112
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03756220
Drug: Combination therapy of vitamin C and thiamine
RxNorm normalized name: combinations of levothyroxine and liothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
Trial: NCT01213030
Drug: [F-18] FMISO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
Trial: NCT01213030
Drug: [F-18] HX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
Trial: NCT00454649
Drug: Axitinib + Capecitabine (Cohort 6)
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
Trial: NCT00454649
Drug: Axitinib + Capecitabine (Cohort 7)
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
Trial: NCT02170909
Drug: BIBR 1048 MS high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03985007
Drug: CDIAG regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
Trial: NCT02552862
Drug: Vivomixx®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
Trial: NCT02552862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
Trial: NCT01069055
Drug: Intravenous lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
Trial: NCT01069055
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
Trial: NCT01744314
Drug: Indomethacin and Pantoprazole
RxNorm normalized name: pantoprazole, amoxicillin and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03948685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03984656
Drug: serratus plane block treatment
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block.
Trial: NCT03551548
Drug: Spironolactone 25mg
RxNorm normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.